CKD-387

DRUG7 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

Endocrine, Nutritional and Metabolic DiseasesType 2 Diabetes MellitusType II DiabetesType2 Diabetes Mellitus

Phase 1

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults

Chong Kun Dang PharmaceuticalType II Diabetes

Start: 2018-08-30End: 2018-09-14Target: 36Updated: 2018-08-24

The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed Condition

CompletedNCT03738449

Chong Kun Dang PharmaceuticalType 2 Diabetes Mellitus

Start: 2019-01-08End: 2019-01-24Updated: 2019-02-21

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition

Chong Kun Dang PharmaceuticalType 2 Diabetes Mellitus

Start: 2019-01-28End: 2019-02-28Target: 20Updated: 2019-02-21

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy Adults

Chong Kun Dang PharmaceuticalType2 Diabetes Mellitus

Start: 2019-01-14End: 2019-02-22Target: 36Updated: 2019-02-21

Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition

CompletedNCT05673369

Chong Kun Dang PharmaceuticalEndocrine, Nutritional and Metabolic Diseases

Start: 2023-02-01End: 2023-02-27Updated: 2024-05-03

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions

CompletedNCT06399055

Chong Kun Dang PharmaceuticalEndocrine, Nutritional and Metabolic Diseases

Start: 2022-09-16End: 2022-10-09Updated: 2024-05-03

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions

CompletedNCT06399068

Chong Kun Dang PharmaceuticalEndocrine, Nutritional and Metabolic Diseases

Start: 2022-09-19End: 2022-10-05Updated: 2024-05-03